Search

Displaying results 9961 - 9970 of 10000 in total
  1. Drug

    Willow bark

    go.drugbank.com/drugs/DB14691
    Approved

    Mixtures: Miller's Formula No. 1
  2. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    2-mg daily dose regimen of etrasimod, with a 32% and 26% remission rate observed in UC 52 and UC 12 trials respectively. … Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P<sub>1,4,5</sub> with no detectable activity on S1P<sub>2</sub> and S1P<sub>3</sub

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-Ring
  3. Drug

    GDC-0425

    go.drugbank.com/drugs/DB14791
    Investigational

    GDC-0425 is under investigation in clinical trial NCT01359696 (A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory

    Categories: Heterocyclic Compounds, 1-Ring
  4. Drug

    Obefazimod

    go.drugbank.com/drugs/DB14828
    Investigational

    ABX-464 is under investigation in clinical trial NCT03905109 (Safety Evaluation of ABX464 in Patients With Moderate to Severe Active Crohn's Disease).

    Categories: Heterocyclic Compounds, 2-Ring
  5. Drug

    Ensartinib

    go.drugbank.com/drugs/DB14860
    ApprovedInvestigational

    [A273963, A273958] Ensartinib is a first-line treatment for anaplastic lymphoma kinase (ALK)-mutated non-small cell lung cancer (NSCLC). … Non-small cell lung cancer (NSCLC) is one of the most frequent subtypes of lung cancers and encompasses a variety of different lung cancers, with notable ones being adenocarcinoma, squamous cell carcinoma

    Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-Ring
  6. Drug

    Pyrotinib

    go.drugbank.com/drugs/DB14993
    Investigational

    Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).

    Categories: Heterocyclic Compounds, 2-Ring
  7. Drug

    Dexpramipexole

    go.drugbank.com/drugs/DB15130
    Investigational

    trial NCT01511029 (Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T

    Categories: Compounds used in a research, industrial, or household setting, Heterocyclic Compounds, 1-Ring
  8. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    Deutivacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) potentiator.

    Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  9. Drug

    2-Hydroxylpropyl-beta-cyclodextrin

    go.drugbank.com/drugs/DB15146
    Investigational

    Adrabetadex is under investigation in clinical trial NCT03887533 (Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1).

    Categories: Compounds used in a research, industrial, or household settingSynonyms: 2-Hydroxypropyl-b-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin
  10. Drug

    Avapritinib

    go.drugbank.com/drugs/DB15233
    ApprovedInvestigational

    [A189327] Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 [L40363] and EMA approval on 24 September 2020.[L41464] … Avapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal

    Categories: MATE 2-K Inhibitors, MATE 1 Inhibitors